Key Healthcare Waivers Face Extension Decisions in Congress and DEA
The future of popular healthcare programs like Acute Hospital Care at Home and telehealth prescribing hangs in the balance as Congress and the Drug Enforcement Administration (DEA) weigh extensions to critical waivers. Recent developments signal potential continuation of these programs, but uncertainty remains regarding the scope and duration of these extensions, leaving healthcare executives awaiting further clarity.
AHCaH Waiver Heads to Senate After House Approval
A proposed five-year extension of the Centers for Medicare & Medicaid Services (CMS) Acute Hospital Care at Home (AHCaH) waiver has passed the House of Representatives and is now under consideration by the Senate. This extension, if approved, would allow eligible hospitals to continue providing acute care services to patients in their homes through December 31, 2030. The AHCaH waiver program, initially launched during the COVID-19 pandemic, has proven popular with both patients and providers, offering a potentially lower-cost and more convenient alternative to traditional hospital stays.
DEA Signals Extension of Virtual Prescribing Waiver
Alongside the AHCaH developments, the DEA has indicated it will extend a waiver currently permitting providers to remotely prescribe controlled medications without requiring an initial in-person visit. This waiver, also implemented during the pandemic to facilitate access to care, has been crucial for patients in rural areas and those with limited mobility. The extension will provide continued flexibility for telehealth-based prescription practices, though the specifics of the extension – including any potential limitations – are still being finalized.
Telehealth Reimbursement Waivers Looming Deadline
Healthcare executives are also closely monitoring the fate of several Medicare waivers related to telehealth use and reimbursement, which are scheduled to expire at the end of January 2026. These waivers have been instrumental in expanding access to telehealth services, particularly for routine care and mental health services. The potential lapse of these waivers could significantly disrupt telehealth programs and potentially limit patient access to care.
“The industry is bracing for a complex period of regulatory change,” stated a senior official. “The decisions made by Congress and the DEA in the coming months will have a profound impact on the future of healthcare delivery.”
Congress is currently moving forward with a bill that aims to address these expiring waivers, but the details and timeline remain fluid. The outcome of these legislative and regulatory efforts will be critical in shaping the landscape of healthcare access and innovation in the years to come.
